Novel Drug Targets for Treatment of Colorectal Cancer

Evotec and Indivumed achieve Milestone in joint strategic Drug Discovery Collaboration

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.

© Pixabay

Under the terms of the collaboration agreement, Evotec received full access to the colorectal cancer ("CRC") multi-omics data of Indivutype. The milestone of selecting three novel drug targets was achieved in less than three months.

The first set of identified targets will now be progressed towards first-in-class therapeutics for the treatment of CRC using Evotec's multimodality drug discovery and development platforms. Four additional candidate targets identified by Indivumed's bioinformatic and analytics will also enter the joint development programme.

Indivumed's commitment to generating high quality and extensive cancer patient information is complementary and synergistic to Evotec's expertise in analysing highly complex multi-omics data. Evotec will be responsible for subsequent partnering of the programmes and/or the platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "The rapid identification of truly novel drug targets reflects the power of our approach to precision medicine that we are pursuing together with Indivumed. The rigorous quality standards employed by Indivumed in the generation of the Indivutype multi-omics patient database enables novel insights into target-disease associations in colorectal cancer which are expected to deliver more effective treatment options."

Anzeige

Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed, said: "We are pleased with the rapid progress being made in our collaboration with Evotec to discover novel drugs that will advance the treatment of colorectal cancer (CRC) patients and potentially other cancer entities. Indivutype has enabled CRC subpopulations to be characterised based on molecular phenotypes with greater precision than has been possible before. As a result, the targets that have been identified are expected to deliver more effective and durable drugs to transform CRC patient care."

Source: Evotec SE

Anzeige

Das könnte Sie auch interessieren

Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige